Cigna says it will not pursue a merger with Humananews2024-11-11T14:54:54+00:00November 11th, 2024|Endpoints News|
ALK-Abelló licenses ARS’ anaphylaxis nasal spray in certain markets for $145Mnews2024-11-11T12:20:00+00:00November 11th, 2024|Endpoints News|
Avid Bioservices to be sold to private equity firms for $1.1Bnews2024-11-07T13:29:18+00:00November 7th, 2024|Endpoints News|
Joe Jimenez’s latest Aditum company lines up T cell engager from Chinanews2024-11-07T12:03:51+00:00November 7th, 2024|Endpoints News|
PrognomiQ raises $34M for lung cancer testnews2024-11-05T14:00:45+00:00November 5th, 2024|Endpoints News|
Nektar divests manufacturing site and reagent arm for $90M news2024-11-05T12:03:51+00:00November 5th, 2024|Endpoints News|
European Commission marks Dec. 6 for Novo-Catalent deal decisionnews2024-11-04T10:58:13+00:00November 4th, 2024|Endpoints News|
Q&A: Jade CEO talks about reverse merger and IgAN drugsnews2024-10-31T18:21:33+00:00October 31st, 2024|Endpoints News|
AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65Mnews2024-10-31T12:00:02+00:00October 31st, 2024|Endpoints News|
Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s placenews2024-10-31T11:27:04+00:00October 31st, 2024|Endpoints News|
